Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical Application of CAIX-Targeted PET Imaging in Tumors
NCT07590310Phase 1Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 68Ga/18F-CAIX-LT-BCH in kidney cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Standardized Uptake Value. Started Mar 2025; status: recruiting.
02
Drugs
68Ga/18F-CAIX-LT-BCH
03
Conditions
kidney cancer
Beyond the preview
Go deeper on NCT07590310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07590310.